CARL ZEISS MEDITEC AG - BR (AFX.DE) Fundamental Analysis & Valuation
FRA:AFX • DE0005313704
Current stock price
23.56 EUR
-0.12 (-0.51%)
Last:
This AFX.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. AFX.DE Profitability Analysis
1.1 Basic Checks
- AFX had positive earnings in the past year.
- AFX had a positive operating cash flow in the past year.
- Each year in the past 5 years AFX has been profitable.
- AFX had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- The Return On Assets of AFX (4.15%) is better than 65.08% of its industry peers.
- With a Return On Equity value of 6.67%, AFX perfoms like the industry average, outperforming 50.79% of the companies in the same industry.
- AFX's Return On Invested Capital of 5.79% is in line compared to the rest of the industry. AFX outperforms 55.56% of its industry peers.
- AFX had an Average Return On Invested Capital over the past 3 years of 7.11%. This is below the industry average of 9.72%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.15% | ||
| ROE | 6.67% | ||
| ROIC | 5.79% |
ROA(3y)6.33%
ROA(5y)7.85%
ROE(3y)9.62%
ROE(5y)11.54%
ROIC(3y)7.11%
ROIC(5y)9.66%
1.3 Margins
- AFX has a Profit Margin of 6.34%. This is comparable to the rest of the industry: AFX outperforms 55.56% of its industry peers.
- In the last couple of years the Profit Margin of AFX has declined.
- AFX has a Operating Margin (10.03%) which is in line with its industry peers.
- In the last couple of years the Operating Margin of AFX has declined.
- AFX has a Gross Margin (52.76%) which is comparable to the rest of the industry.
- In the last couple of years the Gross Margin of AFX has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 10.03% | ||
| PM (TTM) | 6.34% | ||
| GM | 52.76% |
OM growth 3Y-21.67%
OM growth 5Y-5.49%
PM growth 3Y-25.69%
PM growth 5Y-7.11%
GM growth 3Y-3.8%
GM growth 5Y-1.12%
2. AFX.DE Health Analysis
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), AFX is creating some value.
- The number of shares outstanding for AFX remains at a similar level compared to 1 year ago.
- Compared to 5 years ago, AFX has less shares outstanding
- AFX has a better debt/assets ratio than last year.
2.2 Solvency
- AFX has an Altman-Z score of 2.77. This is not the best score and indicates that AFX is in the grey zone with still only limited risk for bankruptcy at the moment.
- AFX's Altman-Z score of 2.77 is in line compared to the rest of the industry. AFX outperforms 55.56% of its industry peers.
- The Debt to FCF ratio of AFX is 4.41, which is a neutral value as it means it would take AFX, 4.41 years of fcf income to pay off all of its debts.
- Looking at the Debt to FCF ratio, with a value of 4.41, AFX is in the better half of the industry, outperforming 61.90% of the companies in the same industry.
- AFX has a Debt/Equity ratio of 0.27. This is a healthy value indicating a solid balance between debt and equity.
- With a decent Debt to Equity ratio value of 0.27, AFX is doing good in the industry, outperforming 63.49% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.27 | ||
| Debt/FCF | 4.41 | ||
| Altman-Z | 2.77 |
ROIC/WACC0.89
WACC6.52%
2.3 Liquidity
- AFX has a Current Ratio of 2.35. This indicates that AFX is financially healthy and has no problem in meeting its short term obligations.
- Looking at the Current ratio, with a value of 2.35, AFX is in the better half of the industry, outperforming 68.25% of the companies in the same industry.
- AFX has a Quick Ratio of 1.44. This is a normal value and indicates that AFX is financially healthy and should not expect problems in meeting its short term obligations.
- AFX's Quick ratio of 1.44 is fine compared to the rest of the industry. AFX outperforms 68.25% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.35 | ||
| Quick Ratio | 1.44 |
3. AFX.DE Growth Analysis
3.1 Past
- AFX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -17.51%.
- The Earnings Per Share has been growing slightly by 3.28% on average over the past years.
- Looking at the last year, AFX shows a small growth in Revenue. The Revenue has grown by 5.89% in the last year.
- Measured over the past years, AFX shows a quite strong growth in Revenue. The Revenue has been growing by 10.78% on average per year.
EPS 1Y (TTM)-17.51%
EPS 3Y-21.2%
EPS 5Y3.28%
EPS Q2Q%-83.33%
Revenue 1Y (TTM)5.89%
Revenue growth 3Y5.39%
Revenue growth 5Y10.78%
Sales Q2Q%-4.79%
3.2 Future
- AFX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.94% yearly.
- The Revenue is expected to grow by 5.17% on average over the next years.
EPS Next Y1.24%
EPS Next 2Y12.96%
EPS Next 3Y14.01%
EPS Next 5Y14.94%
Revenue Next Year2.21%
Revenue Next 2Y3.76%
Revenue Next 3Y4.34%
Revenue Next 5Y5.17%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. AFX.DE Valuation Analysis
4.1 Price/Earnings Ratio
- Based on the Price/Earnings ratio of 16.14, the valuation of AFX can be described as correct.
- 88.89% of the companies in the same industry are more expensive than AFX, based on the Price/Earnings ratio.
- AFX's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 25.79.
- AFX is valuated reasonably with a Price/Forward Earnings ratio of 11.47.
- Based on the Price/Forward Earnings ratio, AFX is valued cheaper than 85.71% of the companies in the same industry.
- The average S&P500 Price/Forward Earnings ratio is at 23.80. AFX is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.14 | ||
| Fwd PE | 11.47 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, AFX is valued cheaper than 87.30% of the companies in the same industry.
- Based on the Price/Free Cash Flow ratio, AFX is valued cheaply inside the industry as 84.13% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 15.81 | ||
| EV/EBITDA | 7.52 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates AFX does not grow enough to justify the current Price/Earnings ratio.
- A more expensive valuation may be justified as AFX's earnings are expected to grow with 14.01% in the coming years.
PEG (NY)12.97
PEG (5Y)4.92
EPS Next 2Y12.96%
EPS Next 3Y14.01%
5. AFX.DE Dividend Analysis
5.1 Amount
- AFX has a Yearly Dividend Yield of 2.33%. Purely for dividend investing, there may be better candidates out there.
- In the last 3 months the price of AFX has falen by -41.22%. A price decline artificially increases the dividend yield. It may be a sign investors do not expect the dividend to last.
- Compared to an average industry Dividend Yield of 1.11, AFX pays a bit more dividend than its industry peers.
- AFX's Dividend Yield is a higher than the S&P500 average which is at 1.91.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.33% |
5.2 History
- The dividend of AFX decreases each year by -1.59%.
Dividend Growth(5Y)-1.59%
Div Incr Years1
Div Non Decr Years4
5.3 Sustainability
- 37.19% of the earnings are spent on dividend by AFX. This is a low number and sustainable payout ratio.
DP37.19%
EPS Next 2Y12.96%
EPS Next 3Y14.01%
AFX.DE Fundamentals: All Metrics, Ratios and Statistics
FRA:AFX (3/18/2026, 7:00:00 PM)
23.56
-0.12 (-0.51%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-12 2026-02-12/dmh
Earnings (Next)05-11 2026-05-11
Inst Owners24.4%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap2.11B
Revenue(TTM)2.20B
Net Income(TTM)141.22M
Analysts66.09
Price Target37.68 (59.93%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.33% |
Yearly Dividend0.6
Dividend Growth(5Y)-1.59%
DP37.19%
Div Incr Years1
Div Non Decr Years4
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-21.46%
Min EPS beat(2)-33.88%
Max EPS beat(2)-9.05%
EPS beat(4)1
Avg EPS beat(4)-16.59%
Min EPS beat(4)-36.67%
Max EPS beat(4)13.25%
EPS beat(8)4
Avg EPS beat(8)-3.62%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)0.89%
Min Revenue beat(2)-1.14%
Max Revenue beat(2)2.92%
Revenue beat(4)3
Avg Revenue beat(4)1.59%
Min Revenue beat(4)-1.14%
Max Revenue beat(4)3.76%
Revenue beat(8)5
Avg Revenue beat(8)-0.32%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-9.12%
PT rev (3m)-32.18%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)-15.87%
EPS NY rev (3m)-20.77%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-1.94%
Revenue NY rev (3m)-2.58%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.14 | ||
| Fwd PE | 11.47 | ||
| P/S | 0.95 | ||
| P/FCF | 15.81 | ||
| P/OCF | 10.04 | ||
| P/B | 1 | ||
| P/tB | 4.35 | ||
| EV/EBITDA | 7.52 |
EPS(TTM)1.46
EY6.2%
EPS(NY)2.05
Fwd EY8.72%
FCF(TTM)1.49
FCFY6.32%
OCF(TTM)2.35
OCFY9.96%
SpS24.91
BVpS23.66
TBVpS5.41
PEG (NY)12.97
PEG (5Y)4.92
Graham Number27.88
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.15% | ||
| ROE | 6.67% | ||
| ROCE | 7.81% | ||
| ROIC | 5.79% | ||
| ROICexc | 5.89% | ||
| ROICexgc | 14.08% | ||
| OM | 10.03% | ||
| PM (TTM) | 6.34% | ||
| GM | 52.76% | ||
| FCFM | 5.98% |
ROA(3y)6.33%
ROA(5y)7.85%
ROE(3y)9.62%
ROE(5y)11.54%
ROIC(3y)7.11%
ROIC(5y)9.66%
ROICexc(3y)7.22%
ROICexc(5y)9.75%
ROICexgc(3y)13.97%
ROICexgc(5y)15.82%
ROCE(3y)9.59%
ROCE(5y)13.04%
ROICexgc growth 3Y-8.4%
ROICexgc growth 5Y5.55%
ROICexc growth 3Y-23.03%
ROICexc growth 5Y-5.34%
OM growth 3Y-21.67%
OM growth 5Y-5.49%
PM growth 3Y-25.69%
PM growth 5Y-7.11%
GM growth 3Y-3.8%
GM growth 5Y-1.12%
F-Score6
Asset Turnover0.65
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.27 | ||
| Debt/FCF | 4.41 | ||
| Debt/EBITDA | 1.61 | ||
| Cap/Depr | 60.61% | ||
| Cap/Sales | 3.44% | ||
| Interest Coverage | 10.38 | ||
| Cash Conversion | 60% | ||
| Profit Quality | 94.37% | ||
| Current Ratio | 2.35 | ||
| Quick Ratio | 1.44 | ||
| Altman-Z | 2.77 |
F-Score6
WACC6.52%
ROIC/WACC0.89
Cap/Depr(3y)109.66%
Cap/Depr(5y)110.76%
Cap/Sales(3y)5.42%
Cap/Sales(5y)4.92%
Profit Quality(3y)64.92%
Profit Quality(5y)71.29%
High Growth Momentum
Growth
EPS 1Y (TTM)-17.51%
EPS 3Y-21.2%
EPS 5Y3.28%
EPS Q2Q%-83.33%
EPS Next Y1.24%
EPS Next 2Y12.96%
EPS Next 3Y14.01%
EPS Next 5Y14.94%
Revenue 1Y (TTM)5.89%
Revenue growth 3Y5.39%
Revenue growth 5Y10.78%
Sales Q2Q%-4.79%
Revenue Next Year2.21%
Revenue Next 2Y3.76%
Revenue Next 3Y4.34%
Revenue Next 5Y5.17%
EBIT growth 1Y14.86%
EBIT growth 3Y-17.44%
EBIT growth 5Y4.69%
EBIT Next Year51.32%
EBIT Next 3Y23.17%
EBIT Next 5Y16.25%
FCF growth 1Y40.11%
FCF growth 3Y7.85%
FCF growth 5Y-0.04%
OCF growth 1Y-15.15%
OCF growth 3Y3.7%
OCF growth 5Y3.29%
CARL ZEISS MEDITEC AG - BR / AFX.DE Fundamental Analysis FAQ
What is the fundamental rating for AFX stock?
ChartMill assigns a fundamental rating of 5 / 10 to AFX.DE.
What is the valuation status of CARL ZEISS MEDITEC AG - BR (AFX.DE) stock?
ChartMill assigns a valuation rating of 6 / 10 to CARL ZEISS MEDITEC AG - BR (AFX.DE). This can be considered as Fairly Valued.
Can you provide the profitability details for CARL ZEISS MEDITEC AG - BR?
CARL ZEISS MEDITEC AG - BR (AFX.DE) has a profitability rating of 4 / 10.
What are the PE and PB ratios of CARL ZEISS MEDITEC AG - BR (AFX.DE) stock?
The Price/Earnings (PE) ratio for CARL ZEISS MEDITEC AG - BR (AFX.DE) is 16.14 and the Price/Book (PB) ratio is 1.
Is the dividend of CARL ZEISS MEDITEC AG - BR sustainable?
The dividend rating of CARL ZEISS MEDITEC AG - BR (AFX.DE) is 4 / 10 and the dividend payout ratio is 37.19%.